

RECEIVED
CENTRAL FAX CENTER

FEB 06 2007

PATENT

Application No. 10/777,792
Amendment dated February 6, 2007
Reply to Office Action of August 7, 2006

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

- 1-118. (Canceled).
119. (Previously Presented) A pharmaceutical composition comprising A β 1-7 linked to CRM197 to form a conjugate.
120. (Previously Presented) The pharmaceutical composition of claim 119, wherein the conjugate comprises a plurality of additional copies of A β 1-7.
121. (Previously Presented) The pharmaceutical composition of claim 119, which comprises at least 10 μ g of A β 1-7.
122. (Previously Presented) The pharmaceutical composition of claim 119, which comprises at least 20 μ g of A β 1-7.
123. (Previously Presented) The pharmaceutical composition of claim 119, which comprises at least 50 μ g of A β 1-7.
124. (Previously Presented) The pharmaceutical composition of claim 119, which comprises at least 100 μ g of A β 1-7.
125. (Previously Presented) The pharmaceutical composition of claim 119, wherein A β 1-7 is linked to CRM197 by chemical crosslinking.
126. (Previously Presented) The pharmaceutical composition of claim 125, wherein the amino terminus of A β 1-7 is linked to CRM197.
127. (Previously Presented) The pharmaceutical composition of claim 125, wherein the carboxyl terminus of A β 1-7 is linked to CRM197.
128. (Previously Presented) The pharmaceutical composition of claim 119, wherein the conjugate is expressed as a fusion protein.

Application No. 10/777,792
Amendment dated February 6, 2007
Reply to Office Action of August 7, 2006

PATENT

129. (Previously Presented) The pharmaceutical composition of claim 128, wherein the amino terminus of A β 1-7 is linked to CRM197.

130. (Previously Presented) The pharmaceutical composition of claim 128, wherein the carboxyl terminus of A β 1-7 is linked to CRM197.

131. (Currently Amended) A pharmaceutical composition comprising (a) A β 1-7 linked to CRM197 to form a conjugate and (b) an adjuvant.

132. (Previously Presented) The pharmaceutical composition of claim 131, wherein the conjugate comprises a plurality of additional copies of A β 1-7.

133. (Previously Presented) The pharmaceutical composition of claim 131, wherein the adjuvant comprises QS-21.

134. (Previously Presented) The pharmaceutical composition of claim 133, which comprises at least 10 μ g of A β 1-7.

135. (Previously Presented) The pharmaceutical composition of claim 133, which comprises at least 20 μ g of A β 1-7.

136. (Previously Presented) The pharmaceutical composition of claim 133, which comprises at least 50 μ g of A β 1-7.

137. (Previously Presented) The pharmaceutical composition of claim 133, which comprises at least 100 μ g of A β 1-7.

138. (Previously Presented) The pharmaceutical composition of claim 133, wherein A β 1-7 is linked to CRM197 by chemical crosslinking.

139. (Previously Presented) The pharmaceutical composition of claim 138, wherein the amino terminus of A β 1-7 is linked to CRM197.

140. (Previously Presented) The pharmaceutical composition of claim 138, wherein the carboxyl terminus of A β 1-7 is linked to CRM197.

Application No. 10/777,792
Amendment dated February 6, 2007
Reply to Office Action of August 7, 2006

PATENT

141. (Previously Presented) The pharmaceutical composition of claim 133, wherein the conjugate is expressed as a fusion protein.

142. (Previously Presented) The pharmaceutical composition of claim 141, wherein the amino terminus of A β 1-7 is linked to CRM197.

143. (Previously Presented) The pharmaceutical composition of claim 141, wherein the carboxyl terminus of A β 1-7 is linked to CRM197.